TLDR
- Oklo stock dropped 9.1% intraday to around $45.68, with over 10.6 million shares changing hands
- The company missed Q4 EPS estimates, reporting ($0.27) vs. the expected ($0.17)
- Insiders sold over 1.2 million shares worth roughly $100.7 million in the last quarter, including CEO and CFO sales
- Two board directors also sold stock on March 30, offloading a combined 14,500 shares
- UBS, B. Riley, and Goldman Sachs all cut price targets, citing high capital needs and execution risks
Oklo has had a tough stretch. After peaking above $190 over the past year, the stock is now down 30% year-to-date and sits well below both its 50-day moving average of $68.12 and its 200-day moving average of $94.27.
The latest sell-off came as several negative data points hit at once — a weak earnings report, fresh analyst target cuts, and a flurry of insider selling that’s hard to ignore.
On the earnings front, Oklo posted a loss of $0.27 per share for the quarter, missing the consensus estimate of ($0.17) by $0.10. That’s not a massive miss in dollar terms, but for a pre-revenue company where execution is everything, it added to nerves.
Analysts didn’t help sentiment either. UBS, B. Riley, and Goldman Sachs all trimmed their price targets, pointing to large capital requirements, rising cash burn, and timeline risks around Oklo’s first-of-a-kind reactor builds. Those concerns are real — Oklo is still pre-revenue, spending heavily, and has yet to secure a full design license from the Nuclear Regulatory Commission.
That said, not everyone turned cold on the stock. Cantor Fitzgerald held firm with an “overweight” rating and a $122 price target as recently as March 18. The overall consensus remains a “Moderate Buy” with an average target of $84.30 — still nearly double the current price. Texas Capital also upgraded to “Strong Buy” back in January.
Insider Selling Adds Pressure
The insider activity has been one of the louder signals in recent weeks. Over the last quarter, insiders collectively sold 1,222,424 shares worth around $100.7 million.
CEO Jacob DeWitte sold 231,657 shares in January at $99.25 each — a 21.88% reduction in his stake. CFO Richard Craig Bealmear followed in March, selling 72,090 shares at $60.00, cutting his holding by 15.74%.
Then on March 30, the same day the stock dropped sharply, two directors joined in. Richard Kinzley sold 4,000 shares for proceeds of $208,360, and John M. Jansen sold 10,500 shares for $540,960.
Insider selling at this pace, especially from the top of the org chart, tends to raise questions — even when executives insist the sales are planned.
What’s Still Working for Oklo
Despite the pressure, Oklo does have real catalysts in its corner.
The company holds $2.6 billion-plus in liquidity, which gives it runway. The Department of Energy has signed off on key approvals, and Oklo’s Meta-backed Ohio project remains on track. The company also recently expanded a fast-reactor partnership with Swedish firm Blykalla.
Its Atomic Alchemy subsidiary is pursuing a radioisotope pilot facility with DOE backing, adding another revenue pathway down the road.
At $7.93 billion in market cap and no revenue yet, the stock is priced for a future that still carries meaningful execution risk. The technical picture — negative MACD, below key moving averages — reflects that tension.
The most recent price as of Monday’s session: $45.68, down 9.1% on the day.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
